SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Champlin, R. E. Articles by Horowitz, M. M. Search for Related Content PubMed PubMed Citation Articles by Champlin, R. E. Articles by Horowitz, M. M. Related Collections Immunobiology Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 12 (June 15), 2000: pp. 3996-4003 TRANSPLANTATION T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities Richard E. Champlin, Jakob R. Passweg, Mei-Jie Zhang, Philip A. Rowlings, Corey J. Pelz, Kerry A. Atkinson, A. John Barrett, Jean-Yves Cahn, William R. Drobyski, Robert Peter Gale, John M. Goldman, Alois Gratwohl, Edward C. Gordon-Smith, P. Jean Henslee-Downey, Roger H. Herzig, John P. Klein, Alberto M. Marmont, Richard J. O'Reilly, Olle Ringdén, Shimon Slavin, Kathleen A. Sobocinski, Bruno Speck, Roy S. Weiner, and Mary M. Horowitz From the International Bone Marrow Transplant Registry; Health Policy Institute (M.J.Z., P.A.R., C.J.P., J.P.K., K.A.S., M.M.H.) and the Division of Hematology/Oncology (W.R.D.), Medical College of Wisconsin, Milwaukee, WI; MD Anderson Cancer Center, Houston, TX (R.E.C.); Kantonsspital Basel, Basel, Switzerland (J.R.P., A.G., B.S.); Coulter Cellular Therapies, Medford, MA (K.A.A.); National Heart, Lung, and Blood Institute, Bethesda, MD (A.J.B.); Hôpital Jean Minjoz, Besancon, France (J.-Y.C.); Center for Advanced Studies in Leukemia, Santa Monica, CA (R.P.G.); Royal Postgraduate Medical School (J.M.G.) and St. Georges Hospital Medical School (E.C.G.-S.), London, UK; University of South Carolina, Columbia, SC (P.J.H.-D.); University of Louisville, Louisville, KY (R.H.H.); Ospedale San Martino, Genoa, Italy (A.M.M.); Memorial Sloan-Kettering Cancer Center, New York, NY (R.J.O.); Huddinge University Hospital, Huddinge, Sweden (O.R.); Hadassah University Hospital, Jerusalem, Israel (S.S.); Tulane University Medical Center, New Orleans, LA (R.S.W.).     Abstract Top Abstract Introduction Patients and methods Results Discussion References T-cell depletion of donor marrow decreases graft-versus-host disease resulting from transplants from unrelated and human leukocyte antigen (HLA)-mismatched related donors. However, there are diverse strategies for T-cell-depleted transplantation, and it is uncertain whether any improve leukemia-free survival (LFS). To compare strategies for T-cell-depleted alternative donor transplants and to compare T-cell depleted with non-T-cell-depleted transplants, we studied 870 patients with leukemia who received T-cell-depleted transplants from unrelated or HLA-mismatched related donors from 1982 to 1994. Outcomes were compared with those of 998 non-T-cell-depleted transplants. We compared LFS using different strategies for T-cell-depleted transplantation considering T-cell depletion technique, intensity of pretransplant conditioning, and posttransplant immune suppression using proportional hazards regression to adjust for other prognostic variables. Five categories of T-cell depletion techniques were considered: narrow-specificity antibodies, broad-specificity antibodies, Campath antibodies, elutriation, and lectins. Strategies resulting in similar LFS were pooled to compare T-cell-depleted with non-T-cell-depleted transplants. Recipients of transplants T-cell depleted by narrow-specificity antibodies had lower treatment failure risk (higher LFS) than recipients of transplants T-cell depleted by other techniques. Compared with non-T-cell-depleted transplants (5-year probability ± 95% confidence interval [CI] of LFS, 31% ± 4%), 5-year LFS was 29% ± 5% (P = NS) after transplants T-cell depleted by narrow-specificity antibodies and 16% ± 4% (P < .0001) after transplants T-cell depleted by other techniques. After alternative donor transplantation, T-cell depletion of donor marrow by narrow-specificity antibodies resulted in LFS rates that were higher than those for transplants T-cell depleted using other techniques but similar to those for non-T-cell-depleted transplants. (Blood. 2000;95:3996-4003) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients and methods Results Discussion References Extensive data indicate that donor T cells cause graft-versus-host disease (GVHD), a major cause of mortality after allogeneic bone marrow transplantation.1,2 Removing T cells from the graft reduces the risk for GVHD. Many techniques for T-cell depletion are available.3-16 Early studies of human leukocyte antigen (HLA)-identical sibling transplants showed that although T-cell depletion decreased GVHD, T-cell-depleted transplants had higher risks for graft failure and leukemia relapse. Leukemia-free survival (LFS) rates were not improved compared with rates in non-T-cell-depleted transplants.17-26 Newer strategies for T-cell-depletedtransplants address problems of graft failure and relapse by removing either fewer or selected subsets of T cells, intensifying pretransplant immune suppression (conditioning), and adding posttransplant immune suppression. Transplants from unrelated or HLA-mismatched related donors (alternative donors) differ from HLA-identical sibling transplants in that they carry a higher risk for GVHD and have associated complications.27,28 There are conflicting reports about whether T-cell depletion improves LFS after alternative donor transplantation.28,29 It was the purpose of this analysis to evaluate different strategies for T-cell-depleted alternative donor transplantation in patients with leukemia by considering techniques for depletion, intensity of the pretransplant conditioning regimen, and posttransplant immune suppression and to determine whether LFS after T-cell-depleted alternative donor transplantation differed from LFS after non-T-cell depleted transplantation.     Patients and methods Top Abstract Introduction Patients and methods Results Discussion References Patients The study included 1868 transplant recipients reported to the International Bone Marrow Transplant Registry (IBMTR) who met the following criteria: (1) diagnosis of chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), or acute lymphoblastic leukemia (ALL); (2) transplantation between 1982 and 1994; (3) unrelated or HLA-mismatched related donor (alternative donor); (4) transplant T-cell depleted by 1 of the 5 techniques described in Table 1 or transplant non-T-cell depleted using posttransplant methotrexate and cyclosporine for GVHD prophylaxis.30 Donor-recipient histocompatibility was determined by results of serologic typing for HLA-A, HLA-B, and HLA-DR, as reported by the transplant center. The study population included 870 recipients of T-cell-depleted transplants reported to the IBMTR by 78 teams and 998 recipients of non-T-cell-depleted transplants reported by 161 teams.31,32 Excluded were recipients of T-cell-depleted transplants using a technique that could not be placed in 1 of the 5 categories in Table 1 (n = 23) and patients with missing information regarding relapses (n = 18). Median follow-up time of survivors was 24 months (range, 4 to 132 months).                                View this table: [in this window] [in a new window]   Table 1. Techniques of T-cell depletion Strategies for T-cell depletion Depletion techniques. Five categories of T-cell depletion techniques (described in Table 1) were considered: narrow-specificity antibodies targeting T cells or T-cell subsets; broad-specificity antibodies targeting T cells and other immune cells; Campath antibodies with very broad specificity; counterflow elutriation separating cells based on size and density; and lectin fractionation, agglutinating T cells, used commonly in combination with sheep red blood cell rosetting. Intensification of pretransplant conditioning. Pretransplant conditioning regimens were considered in 3 categories: standard intensity radiation regimens, corresponding to 12 Gy fractionated or 10 Gy unfractionated total body irradiation and 100 to 120 mg/kg cyclophosphamide; high-intensity radiation regimens with either higher total body irradiation doses or drugs in addition to cyclophosphamide; and busulfan and cyclophosphamide without radiation. Posttransplant immune suppression to prevent GVHD. Two categories were considered: any or none. Eighty-three percent of patients receiving posttransplant immune suppression were administered cyclosporine with or without other drugs. Outcomes The primary outcome of this study was LFS. Other outcomes analyzed were graft failure, acute and chronic GVHD, transplant-related mortality (TRM), relapse, and survival. Results of survival analyses were virtually identical to LFS analyses and are not presented. Graft failure was analyzed in patients surviving 21 days after transplantation using published criteria.33 Primary nonengraftment and transient engraftment were considered graft failures. Acute GVHD was defined as moderate to severe (grades 2 to 4) disease using published criteria; patients surviving more than 21 days with engraftment were considered at risk.34,35 Chronic GVHD was determined by clinical criteria in patients surviving more than 90 days with engraftment.36 TRM was defined as death before relapse. Relapse was defined as hematologic or clinical recurrence at any site or as initiation of treatment for relapse, whichever occurred first; patients in continuous complete remission were censored at death or, for survivors, at last follow-up. LFS was defined as survival in continuous complete remission; relapse and death from causes other than leukemia were considered treatment failures, whereas patients alive and in remission were censored at last follow-up. The International Bone Marrow Transplant Registry The International Bone Marrow Transplant Registry is a voluntary working group of more than 350 transplant teams worldwide that contribute detailed data on their allogeneic bone marrow transplants to the Statistical Center at the Medical College of Wisconsin. Participants are required to report all consecutive transplants; compliance is monitored by on-site audits. Approximately two thirds of all active transplant centers register their transplants with the IBMTR. The IBMTR database includes 40% to 45% of all recipients of allogeneic transplants since 1970. Patients are followed up longitudinally each year. Computerized error checks, physician review of submitted data, and on-site audits of participating centers ensure data quality. To participate in this study, centers had to provide current follow-up on more than 90% of all eligible patients. Statistical methods Cox proportional hazards regression was used to assess the association of T-depletion technique with treatment failure (inverse of LFS).37,38 Potential confounding factors considered were leukemia type (ALL, AML, CML), pretransplant disease state (1st remission or chronic phase, 2nd remission or accelerated phase, not in remission or blast phase), patient age (by decade), Karnofsky performance score (90% vs less than 90%), year of transplantation (1982-1988 vs 1989-1994; the breakpoint was determined by using the regression model with the largest partial likelihood), white blood cell count at diagnosis (more than vs less than or equal to 50 × 109/L for acute leukemia, more than vs less than or equal to 200 × 109/L for CML), donor age (by decade), donor-recipient sex match, donor-recipient relationship, and HLA histocompatibility (related, 0 to 1 antigen mismatch; related, 2 antigen mismatch; unrelated, matched; unrelated mismatched), intensity of conditioning regimen (see Table 2), cell dose (greater than or equal to vs less than median), use of posttransplant immune suppression (any vs none), and prophylactic use of growth factors (any vs none). Forward stepwise variable selection was used to determine which of these covariates were associated with outcome (P = .05 was considered statistically significant). Covariates for T-cell depletion technique were included in each stepwise model. Tests of the appropriateness of the proportional hazards model were made by adding a time-dependent covariate for each significant covariate. Interactions between technique of T-cell depletion and other significant covariates in the model were considered. There were no significant interactions between technique of T-cell depletion, intensity of conditioning regimen, and use of posttransplant immune suppression. Pairwise comparisons between T-cell depletion techniques were made from a final multivariate Cox model, adjusting for relevant risk factors.                                View this table: [in this window] [in a new window]   Table 2. Patient, disease, and transplant characteristics Recipients of bone marrow T-cell depleted by narrow-specificity antibodies had a lower treatment failure risk than recipients of marrow T-cell depleted by other techniques. Pairwise comparisons showed treatment failure risks to be similar in recipients of transplants T-cell depleted by broad-specificity antibodies, Campath antibodies, elutriation, or lectins (Table 3). In-depth comparisons of other outcomes according to specific T-cell depletion technique were not performed. For subsequent comparison with non-T-cell-depleted transplants, T-cell depletion techniques were partitioned into narrow-specificity antibodies and other T-cell depletion techniques.                                View this table: [in this window] [in a new window]   Table 3. Comparison of T-cell-depletion methods in multivariate analysis of treatment failure* Patient, disease, and transplant characteristics of patients receiving T-cell-depleted and non-T-cell-depleted transplants were compared using the 2 statistic for categorical variables and the Mann-Whitney U test for continuous variables (Table 2). Univariate (unadjusted) probabilities of outcomes were calculated using the Kaplan-Meier estimator, and 95% confidence limits (CI) were calculated using the standard error of the survivor function by Greenwood formula. Adjusted probabilities of survival were calculated using the multivariate Cox models described below, stratified on T-cell depletion and weighted by the sample proportion value for each prognostic factor; 95% CI for adjusted survival probabilities and P values of pairwise comparisons were derived from pointwise estimates and were calculated using standard techniques.39 These adjusted probabilities estimate the likelihood of outcomes in populations with similar prognostic factors. Comparisons of the effects of T-cell depletion by narrow-specificity antibodies, T-cell depletion by other techniques, and non-T-cell-depleted transplants on graft failure, acute GVHD, chronic GVHD, relapse, survival, and LFS were made using Cox regression model building procedures as described above. The proportionality assumption did not hold for T-cell depletion effects in models of relapse and LFS, indicating that the effect of T-cell depletion differed in various posttransplant time intervals. To determine periods in which the relative risks of treatment failure and death between T-cell-depleted and T-cell-nondepleted transplants were constant, a series of Cox models with different cut-off points for time-dependent T-cell depletion effects were fit. The final model chosen was the one giving the largest partial likelihood.     Results Top Abstract Introduction Patients and methods Results Discussion References Patient, disease, and transplant characteristics of the study population are shown in Table 2. There were statistically significant differences between recipients of T-cell-depleted and non-T-cell-depleted transplants in distributions of patient age, pretransplant performance score, leukemia type and stage, year of transplantation, intensity of pretransplant conditioning, donor-recipient relationship, and HLA histocompatibility. Patients receiving T-cell-depleted transplants were more likely to have the favorable characteristics of younger age, performance score at least 90%, and negative donor and recipient CMV serology. However, T-cell-depleted transplant recipients also were more likely to have advanced leukemia and greater donor-recipient HLA disparity. There were relatively few 3-antigen mismatched-related donor transplants in the study population (n = 110, 6%), but most (n = 98) received T-cell-depleted transplants. Recipients of T-cell-depleted transplants more frequently received high-intensity conditioning regimens. Table 3 shows results of the multivariate regression model of treatment failure comparing the 5 techniques of T-cell depletion. T-cell depletion using narrow-specificity antibodies was used as baseline and was assigned a relative risk of treatment failure (inverse of LFS) of 1.00. Treatment failure risks for the other 4 techniques were significantly higher (RR, 1.37 to 1.65) but were comparable to each other. Adjusted 5-year probabilities of LFS are shown in Table 3 and Figure 1. Other significant covariates were pretransplant leukemia state, recipient age, pretransplant Karnofsky performance score and donor-recipient relationship and histocompatibility. Neither intensity of pretransplant conditioning nor posttransplant immune suppression were significantly associated with treatment failure and so were not included in the final models. For subsequent comparison with non-T-cell-depleted transplants, T-cell depletion techniques were therefore considered in 2 groups: those depleted using narrow-specificity antibodies and those depleted with other techniques. View larger version (16K): [in this window] [in a new window]   Fig 1. Adjusted 5-year probabilities of LFS by T-cell-depletion technique. Adjusted probability of leukemia-free survival by T-cell-depletion technique, estimated from the multivariate model assuming a distribution of prognostic factors equal to that in the entire study population. Table 4 shows results of the multivariate analysis of graft failure, grades 2 to 4 acute and chronic GVHD, TRM, relapse, and LFS in recipients of T-cell-depleted transplants compared to recipients of non-T-cell-depleted transplants adjusted for relevant prognostic variables. Analyses of survival gave results almost identical to those of LFS and are not shown. Graft failure risk was increased in recipients of T-cell-depleted transplants, less so in those depleted with narrow-specificity techniques than in those depleted using other techniques. Both T-cell depletion groups had lower risks for grades 2 to 4 acute GVHD compared to recipients of non-T-cell-depleted transplants. Risks for grades 3 and 4 acute GVHD were also decreased. Unadjusted 100-day probabilities of grades 3 and 4 acute GVHD were 35% ± 4% after non-T- cell-depleted transplantation, 19% ± 4% after T-cell-depleted transplantation using narrow-specificity antibodies (P < .0001 forcomparison with non-T-cell-depleted transplants), and 21% ± 5% after other T-cell-depleted transplants (P < .0001 for comparison with non-T-cell-depleted transplants; P = NS for comparison with T-cell-depleted transplants using narrow-specificity antibodies).                                View this table: [in this window] [in a new window]   Table 4. Multivariate analysis comparing graft failure, acute and chronic GVHD, relapse, and treatment failure after T-cell-depleted versus non-T-cell-depleted alternative donor transplants* Recipients of marrow T-cell depleted by narrow-specificity antibodies had higher risks for chronic GVHD than patients receiving non-T-cell-depleted transplants. Recipients of marrow T-cell depleted by other techniques had similar risks for chronic GVHD as did recipients of non-T-cell-depleted transplants. Early TRM is often used to assess the impact of multiple transplant-related complications, such as slow or incomplete engraftment, GVHD, and infections. Unadjusted probabilities of 100-day TRM were 33% ± 3% after non-T-cell- depleted transplantation, 35% ± 5% after T-cell-depleted transplantation using narrow-specificity antibodies (P = NS), and 48% ± 5% after other T-cell-depleted transplantation (P < .0001 for comparison with non-T-cell-depleted transplantation; P < .0007 for comparison with transplants T-cell depleted with narrow-specificity antibodies). TRM was similar in recipients of T-cell-depleted transplants using narrow-specificity antibodies compared with non-T-cell-depleted transplants (adjusted RR, 1.18; 95% CI, 0.99 to 1.39; P = NS) but higher in recipients of marrow T-cell depleted by other methods (adjusted RR, 1.60; 95% CI, 1.36 to 1.88; P < .0001). The effect of T-cell depletion on relapse and LFS was time dependent. Effects differed in the first 2 months after transplantation and thereafter. Outcomes are therefore best compared using adjusted probabilities of relapse and LFS. After adjustment for significant covariates, 5-year probabilities (95% CI) of relapse were 31% ± 5% for recipients of non-T-cell-depleted transplants, 28% ± 7% (P = NS) for recipients of transplants T-cell depleted by narrow-specificity antibodies, and 51% ± 11% (P < .001) for recipients of transplants T-cell depleted by other techniques. Adjusted 5-year probabilities of LFS were 31% ± 4% for recipients of non-T-cell-depleted transplants, 29% ± 5% (P = NS) for recipients of transplants T-cell depleted by narrow-specificity antibodies, and 16% ± 4% (P < .0001) for recipients of transplants T-cell depleted by other techniques (Figure 2). View larger version (15K): [in this window] [in a new window]   Fig 2. Adjusted 5-year probabilities of LFS after T-cell depleted and non-T-cell-depleted transplants. Adjusted probabilities of LFS for patients receiving non-T-cell-depleted transplants, transplants T-cell depleted by narrow-specificity antibodies, or transplants T-cell depleted by other techniques, estimated from the multivariate model assuming a distribution of prognostic factors equal to that in the entire study population. Table 5 shows univariate outcome probabilities by pretransplant disease state and degree of donor-recipient HLA disparity. Patterns of graft failure and GVHD were similar regardless of donor type. There were no differences in relapse probabilities between recipients of non-T-cell-depleted transplants and recipients of transplants T-cell depleted by narrow-specificity antibodies, regardless of donor type. Relapse rates were higher in recipients of transplants T-cell depleted by other techniques. Probabilities of LFS were similar between non-T-depleted- and narrow-specificity antibody-depleted-transplants and transplants T-cell depleted by other techniques with significantly lower probabilities of LFS, regardless of donor type. There was no significant difference in these results when each leukemia type was considered separately or when related and unrelated transplants were considered separately.                                View this table: [in this window] [in a new window]   Table 5. Univariate outcome probabilities by donor type and disease state     Discussion Top Abstract Introduction Patients and methods Results Discussion References Previous studies of transplantation using HLA-identical sibling donors showed that T-cell depletion of donor marrow decreased GVHD but increased graft failure and relapse and did not improve LFS. Recipients of transplants from donors other than HLA-identical siblings have higher risks for GVHD,27,28 leading to the hypothesis that T-cell depletion may be more beneficial in this setting. A number of uncontrolled studies have addressed these issues,40-47 and a randomized multicenter trial of T-cell depletion in unrelated donor transplants is ongoing. Various T-cell depletion techniques have been studied. Depending on the method, a different spectrum of T, B, NK, and accessory cells is depleted, with varying effects on engraftment and immune reconstitution. We found that recipients of transplants T-cell depleted by narrow-specificity antibodies had lower treatment failure risks than recipients of transplants T-cell depleted by other techniques. The narrow-specificity antibody techniques were defined by their relative specificity for T-cells versus other immune cells, though, depending on the antibody used, small proportions of NK or other cells may also be removed with these methods. Other T-cell-depletion techniques tend to remove larger numbers and a more diverse population of lymphocytes from the graft. Recipients of transplants depleted by narrow-specificity antibodies generally were at lower risk for relapse than were recipients of transplants depleted by other methods (Table 4). Because we lacked data on T-cell dose and phenotype in the grafts, we were unable to address whether this difference resulted from quantitative or qualitative differences, or both, in donor T cells. The absence of significant interactive effects of T-cell-depletion techniques and the intensity of the conditioning regimen or posttransplant immune suppression indicated that estimated effects were independent. We compared the 870 recipients of T-cell-depleted alternative donor transplants with 998 concurrently treated recipients of non-T-cell-depleted transplants using methotrexate and cyclosporine for GVHD prophylaxis. Recipients of transplants T-cell depleted by narrow-specificity antibodies had slightly more graft failure, less acute GVHD, more chronic GVHD but similar risks for relapse TRM and LFS. Recipients of T-cell-depleted transplants using other techniques had substantially higher risks for graft failure, less acute GVHD, similar risks for chronic GVHD, higher rates of relapse and TRM, and lower LFS than recipietns of non-T-cell-depleted transplants. It is uncertain why there is an increased risk for chronic GVHD with transplants T-cell depleted by narrow-specificity antibodies. This effect occurred primarily in 2 to 3 antigen-mismatched- related and antigen-mismatched-unrelated transplants. Acute and chronic GVHD are related processes. Conceivably, the decreased reduction of T-lymphocytes delayed but did not prevent the development of GVHD, with manifestations appearing after day 100. Remaining NK cells or retained subclasses of T cells might contribute. Alternatively, this form of transplant might result in dysregulated immune reconstitution and, consequently, more GVHD. This increased chronic GVHD might explain, in part, the lower relapse rate with this versus other methods of T-cell depletion. This study analyzed patients who underwent transplantation between 1982 and 1994. There was a significant change in outcome of T-cell-depleted and non-T-cell-depleted transplants over time. The risk for treatment failure in patients who underwent transplantation after 1989 was lower than in patients who underwent it from 1982 to 1988, but there was no significant interaction between year of transplantation and T-cell depletion effect. All transplant years were therefore analyzed simultaneously. There were no significant interactions between technique of T-cell depletion and disease. In other words, the relative efficacy of T-cell-depleted and non-T-cell-depleted transplants was the same throughout the study period and for all diseases. The data analyzed have several limitations. First, recipients of T-cell-depleted transplants differed significantly from recipients of non-T-cell-depleted transplants in some patient, disease, and transplant characteristics. Recipients of T-cell-depleted transplants had more advanced disease and, most important, received grafts from donors with greater HLA disparities (Table 2), putting them at inherently higher risk for adverse outcomes. There were relatively few patients with fully haplo-disparate (3-antigen disparate) grafts in either group, but they were more frequent in the T-cell-depleted cohort. Although we adjusted for these differences in multivariate analysis, we might still have underestimated an effect of T-cell depletion, especially in the more HLA-disparate transplants. Second, it is likely that techniques of T-cell depletion changed over time in ways not fully described by the categories in Table 1. Intensity of T-cell depletion was less in some recently described approaches.48-53 T-lymphocytes mediate not only GVHD but also engraftment and graft-versus-leukemia, and attempts have been made to engineer marrow to transplant predetermined T-lymphocyte doses or to add T-lymphocytes after transplantation.49,54 Preliminary reports describe using high doses of peripheral CD34+ cells extensively depleted of T cells or T-cell-depleted transplants engineered to retain graft-facilitating cells.55-57 Consideration of CD34+ cell dose, T-cell dose, and T-cell subset analysis is desirable, but detailed data were unavailable for this study. Approaches producing similar cell products were grouped to provide sufficient power for the analyses. Although comparison of techniques within each group showed no outcome difference, it is possible that we missed a particularly advantageous (or disadvantageous) approach applied in a small number of patients. Finally, this was a nonrandomized study. Although we carefully considered potential confounding by a large number of variables, it is possible that some of the observed effects were caused by other unmeasured factors. Transplants using donors other than HLA-identical siblings are increasingly performed. The optimal strategy for alternative donor transplantation is unknown. This study demonstrates that T-cell depletion reduced the risk for acute GVHD, the major cause of morbidity and mortality after transplantation. It is unique in comparing large groups of patients receiving T-cell-depleted with non-T-cell-depleted alternative donor transplants. The effects of T-cell depletion appeared similar regardless of disease, donor-recipient relationship, and donor-recipient HLA match. T-cell depletion using narrow-specificity antibodies resulted in LFS rates similar to those for non-T-cell depleted transplants using methotrexate and cyclosporine for GVHD prophylaxis. LFS rates after transplants that were T-cell depleted using other techniques were lower. It appears, therefore, from this retrospective study that despite reduced acute GVHD, there was no advantage in LFS or survival rates with T-cell-depleted transplants over unmodified grafts with cyclosporine and methotrexate after transplantation. A prospective randomized study addressing this issue is in progress. Innovations to enhance engraftment and immune reconstitution may improve results of T-cell-depleted transplants and permit effective use of more thoroughly depleted grafts or use of broadly reactive antibodies for depletion. Further studies are warranted to assess novel strategies for graft engineering to enhance the results of allogeneic hematopoietic stem cell transplantation.     Footnotes Submitted January 1, 1998; accepted February 10, 2000. Bruno Speck died September 18, 1998. Supported by Public Health Service grants P01-CA40053 and U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute of the United States Department of Health and Human Services and by grants from Alpha Therapeutic Corporation; Amgen; Anonymous; Basel Cancer League, Switzerland; Baxter Healthcare Corporation; Bayer Corporation; Berlex Laboratories; BioWhitakker; Blue Cross and Blue Shield Association; Lynde and Harry Bradley Foundation; Bristol-Myers Squibb Company; Cell Therapeutics; Centeon; Center for Advanced Studies in Leukemia; Chimeric Therapies; Chiron Therapeutics; Ciba-Geigy Jubilaeums Foundation, Switzerland; Charles E. Culpeper Foundation; Eleanor Naylor Dana Charitable Trust; Eppley Foundation for Research; Free Academic Society, Basel, Switzerland; Genentech; Glaxo Wellcome Company; Human Genome Sciences; ICN Pharmaceuticals; Immunex Corporation; Kettering Family Foundation; Kirin Brewery Company; Robert J. Kleberg Jr and Helen C. Kleberg Foundation; Herbert H. Kohl Charities; Nada and Herbert P. Mahler Charities; Milstein Family Foundation; Milwaukee Foundation/Elsa Schoeneich Research Fund; NeXstar Pharmaceuticals; Samuel Roberts Noble Foundation; Novartis Pharmaceuticals; Orphan Medical; Ortho Biotech, Inc; John Oster Family Foundation; Jane and Lloyd Pettit Foundation; Alirio Pfiffer Bone Marrow Transplant Support Association; Pfizer; Pharmacia and Upjohn; Principal Mutual Life Insurance Company; RGK Foundation; Rockwell Automation Allen Bradley Company; Roche Laboratories; SangStat Medical Corporation; Schering-Plough Oncology; Searle; SmithKline Beecham Pharmaceutical; Stackner Family Foundation; Starr Foundation; Joan and Jack Stein Foundation; Swiss National Fund for Research; SyStemix; United Resource Networks; and Wyeth-Ayerst Laboratories. Reprints: Mary M. Horowitz, International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Patients and methods Results Discussion References 1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667[Medline] [Order article via Infotrieve]. 2. Gratwohl A, Hermans J, Apperley J, et al. for the Working Party on Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood. 1995;86:813[Abstract/Free Full Text]. 3. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am. 1990;4:687[Medline] [Order article via Infotrieve]. 4. O'Reilly RJ. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol. 1992;29(suppl 1):20[Medline] [Order article via Infotrieve]. 5. Martin PJ, Hansen JA, Buckner D, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664[Abstract/Free Full Text]. 6. Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet. 1982;1:700[Medline] [Order article via Infotrieve]. 7. Waldmann H, Polliak A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet. 1984;2:483[Medline] [Order article via Infotrieve]. 8. Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;78:2139[Abstract/Free Full Text]. 9. De Witte T, Hoogenhout J, de Pauw B, et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood. 1986;67:1302[Abstract/Free Full Text]. 10. Maraninchi D, Mawas C, Guyotat D, et al. Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone-marrow transplantation. Transplant Int. 1988;1:91[Medline] [Order article via Infotrieve]. 11. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992;10:1191[Abstract]. 12. Filipovich AH, Vallera D, McGlave P, et al. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: the correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation. 1990;50:410[Medline] [Order article via Infotrieve]. 13. Wagner JE, Santos GW, Noga SJ, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood. 1990;75:1370[Abstract/Free Full Text]. 14. Herve P, Flesch M, Cahn JY, et al. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease: a pilot study in ten patients. Transplantation. 1985;39:138[Medline] [Order article via Infotrieve]. 15. Slocombe GW, Newland AC, Yeatman NWJ, Macey M, Jones HM, Knott L. Allogeneic bone marrow transplantation for adult leukaemia with soy bean lectin fractionated marrow. Bone Marrow Transplant. 1986;1:31[Medline] [Order article via Infotrieve]. 16. Jansen J, Hanks S, Akard L, et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:271[Medline] [Order article via Infotrieve]. 17. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplant in leukemia. Blood. 1991;78:2120[Abstract/Free Full Text]. 18. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med. 1986;105:20. 19. Ringdén O, Remberger M, Aschan J, Ljungman P, Lonnqvist B, Markling L. Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplantation. 1994;58:887[Medline] [Order article via Infotrieve]. 20. Atkinson K, Biggs J, Cooley M, et al. A comparative study of T-cell depleted and non-depleted marrow transplantation for hematological malignancy. Aust N Z J Med. 1987;17:16[Medline] [Order article via Infotrieve]. 21. Racadot E, Herve P, Beaujean F, et al. Prevention of graft-versus-host disease in HLA-matched bone marrow transplantation for malignant diseases: a multicentric study of 62 patients using 3-pan-T monoclonal antibodies and rabbit complement. J Clin Oncol. 1987;5:426[Abstract]. 22. Bunjes D, Hertenstein B, Wiesneth M, et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant. 1995;15:563[Medline] [Order article via Infotrieve]. 23. Marks DI, Hughes TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in the first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol. 1992;81:383[Medline] [Order article via Infotrieve]. 24. Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1:53[Medline] [Order article via Infotrieve]. 25. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175[Medline] [Order article via Infotrieve]. 26. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806. 27. Ochs L, Shu OX, Miller J, et al. Late infections after allogeneic bone marrow transplantation: Comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979[Abstract/Free Full Text]. 28. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593[Abstract/Free Full Text]. 29. Cavazzana-Calvo M, Bordigoni P, Michel G, et al. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Br J Haematol. 1996;93:131[Medline] [Order article via Infotrieve]. 30. Ringdén O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81:1094[Abstract/Free Full Text]. 31. Horowitz MM, Bortin MM. The role of registries in evaluating the results of bone marrow transplantation. In: Treleaven J,Barrett J, eds. Bone Marrow Transplantation in Practice. Edinburgh: Churchill Livingstone; 1992:367. 32. Clift RA, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989;4:445[Medline] [Order article via Infotrieve]. 33. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606[Abstract/Free Full Text]. 34. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295[Medline] [Order article via Infotrieve]. 35. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397[Medline] [Order article via Infotrieve]. 36. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459[Abstract/Free Full Text]. 37. Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972;34:187. 38. Andersen PK, Borgan O, Gill R, Keiding N. Statistical Models Based on Counting Processes. New York: Springer-Verlag; 1992. 39. Klein JP, Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data. New York: Springer-Verlag; 1996. 40. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:1980[Abstract/Free Full Text]. 41. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991;7:443[Medline] [Order article via Infotrieve]. 42. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322:485[Abstract]. 43. Quinones RR, Gutierrez RH, Dinndorf PA, et al. Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood. 1993;82:307[Abstract/Free Full Text]. 44. Henslee-Downey PJ, Parrish RS, MacDonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61:738[Medline] [Order article via Infotrieve]. 45. Fleming DR, Henslee-Downey PJ, Romond EH, et al. Allogeneic bone marrow transplantation with T-cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplant. 1996;17:917[Medline] [Order article via Infotrieve]. 46. Spencer A, Szydlo RM, Brookes PA, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood. 1995;86:3590[Abstract/Free Full Text]. 47. Bradley BA, Hows JM, Gore SM, et al. Current status of unrelated-donor bone marrow transplantation: the International Marrow Unrelated Search and Transplant (IMUST) Study. Clin Transplants. 1992;91. 48. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood. 1995;85:3302[Abstract/Free Full Text]. 49. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506[Medline] [Order article via Infotrieve]. 50. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood. 1994;83:3090[Abstract/Free Full Text]. 51. Clark RE, Pender N. Transplantation of T-lymphocyte depleted marrow with an addback of T cells. Hematol Oncol. 1995;13:219[Medline] [Order article via Infotrieve]. 52. Champlin R, Giralt S, Przepiorka D, et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus-leukemia. Prog Clin Biol Res. 1992;377:385[Medline] [Order article via Infotrieve]. 53. Dreger P, Viehmann K, Steinmann J, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol. 1995;23:147[Medline] [Order article via Infotrieve]. 54. Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Clin Transpl. 1996;24:281. 55. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical `three loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte-colony-stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948[Abstract/Free Full Text]. 56. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436[Abstract/Free Full Text]. 57. Henslee-Downey PJ, Abhjyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864[Abstract/Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. J. Tsao, J. A. Allen, K. A. Logronio, L. C. Lazzeroni, and J. A. Shizuru Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow PNAS, March 3, 2009; 106(9): 3288 - 3293. [Abstract] [Full Text] [PDF] J. A. Wade, C. Katovich Hurley, S. K. Takemoto, J. Thompson, S. M. Davies, T. C. Fuller, G. Rodey, D. L. Confer, H. Noreen, M. Haagenson, et al. HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation Blood, May 1, 2007; 109(9): 4064 - 4070. [Abstract] [Full Text] [PDF] H. E. Heslop To T-cell deplete or not Blood, November 1, 2005; 106(9): 2932 - 2932. [Full Text] [PDF] S. Z. Pavletic, S. L. Carter, N. A. Kernan, J. Henslee-Downey, A. M. Mendizabal, E. Papadopoulos, R. Gingrich, J. Casper, S. Yanovich, D. Weisdorf, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation Blood, November 1, 2005; 106(9): 3308 - 3313. [Abstract] [Full Text] [PDF] H. M. Lokhorst, C. M. Segeren, L. F. Verdonck, B. van der Holt, R. Raymakers, M. H.J. van Oers, R. M.Y. Barge, H. C. Schouten, P. H.M. Westveer, M. M.C. Steijaert, et al. Partially T-Cell-Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM J. Clin. Oncol., May 1, 2003; 21(9): 1728 - 1733. [Abstract] [Full Text] [PDF] P. Lang, R. Handgretinger, D. Niethammer, P. G. Schlegel, M. Schumm, J. Greil, P. Bader, C. Engel, H. Scheel-Walter, M. Eyrich, et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia Blood, February 15, 2003; 101(4): 1630 - 1636. [Abstract] [Full Text] [PDF] S. J. Lee, D. Zahrieh, E. P. Alyea, E. Weller, V. T. Ho, J. H. Antin, and R. J. Soiffer Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs Blood, September 26, 2002; 100(8): 2697 - 2702. [Abstract] [Full Text] [PDF] E. Zorn, K. S. Wang, E. P. Hochberg, C. Canning, E. P. Alyea, R. J. Soiffer, and J. Ritz Infusion of CD4+ Donor Lymphocytes Induces the Expansion of CD8+ Donor T Cells with Cytolytic Activity Directed against Recipient Hematopoietic Cells Clin. Cancer Res., July 1, 2002; 8(7): 2052 - 2060. [Abstract] [Full Text] [PDF] M. Guimond, A. Balassy, M. Barrette, S. Brochu, C. Perreault, and D. C. Roy P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells Blood, June 28, 2002; 100(2): 375 - 382. [Abstract] [Full Text] [PDF] N. Bunin, M. Carston, D. Wall, R. Adams, J. Casper, N. Kamani, R. King, and the National Marrow Donor Program Working Group Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission Blood, May 1, 2002; 99(9): 3151 - 3157. [Abstract] [Full Text] [PDF] R. Chakraverty, K. Peggs, R. Chopra, D. W. Milligan, P. D. Kottaridis, S. Verfuerth, J. Geary, D. Thuraisundaram, K. Branson, S. Chakrabarti, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood, February 1, 2002; 99(3): 1071 - 1078. [Abstract] [Full Text] [PDF] V. T. Ho and R. J. Soiffer The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood, December 1, 2001; 98(12): 3192 - 3204. [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Champlin, R. E. Articles by Horowitz, M. M. Search for Related Content PubMed PubMed Citation Articles by Champlin, R. E. Articles by Horowitz, M. M. Related Collections Immunobiology Transplantation Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020